Cancer in refugees in Jordan and Syria between 2009 and 2012: challenges and the way forward in humanitarian emergencies

被引:0
|
作者
Spiegel, Paul [1 ]
Khalifa, Adam [2 ]
Mateen, Farrah J. [3 ,4 ]
机构
[1] Off United Nations High Commissioner Refugees, CH-1211 Geneva, Switzerland
[2] Off United Nations High Commissioner Refugees, Damascus, Syria
[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
来源
LANCET ONCOLOGY | 2014年 / 15卷 / 07期
关键词
AFGHAN REFUGEES; HEALTH;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Treatment of non-communicable diseases such as cancer in refugees is neglected in low-income and middle-income countries, but is of increasing importance because the number of refugees is growing. The UNHCR, through exceptional care committees (ECCs), has developed standard operating procedures to address expensive medical treatment for refugees in host countries, to decide on eligibility and amount of payment. We present data from funding applications for cancer treatments for refugees in Jordan between 2010 and 2012, and in Syria between 2009 and 2011. Cancer in refugees causes a substantial burden on the health systems of the host countries. Recommendations to improve prevention and treatment include improvement of health systems through standard operating procedures and innovative financing schemes, balance of primary and emergency care with expensive referral care, development of electronic cancer registries, and securement of sustainable funding sources. Analysis of cancer care in low-income refugee settings, particularly in sub-Saharan Africa, is needed to inform future responses.
引用
下载
收藏
页码:E290 / E297
页数:8
相关论文
共 23 条
  • [21] Comparison of recall, biopsy, and cancer detection rates in the Southern Derbyshire screening programme between 2006 and 2009 using hard-copy mammography and in 2009 to 2012 following the full introduction of soft-copy reporting
    Turnbull, A. E.
    Puri, S.
    Bagnall, M.
    York, J.
    Farmer, S.
    Horsley, N.
    BREAST CANCER RESEARCH, 2012, 14
  • [22] Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012
    Nobumichi Tanaka
    Yasushi Nakai
    Makito Miyake
    Satoshi Anai
    Takeshi Inoue
    Tomomi Fujii
    Noboru Konishi
    Kiyohide Fujimoto
    BMC Cancer, 17
  • [23] Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012
    Tanaka, Nobumichi
    Nakai, Yasushi
    Miyake, Makito
    Anai, Satoshi
    Inoue, Takeshi
    Fujii, Tomomi
    Konishi, Noboru
    Fujimoto, Kiyohide
    BMC CANCER, 2017, 17